Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-09
DOI
10.3389/fimmu.2022.823618
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
- (2021) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- (2021) Stephen V. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer
- (2021) Seung Tae Kim et al. CLINICAL CANCER RESEARCH
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
- (2021) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models
- (2021) Axel Hyrenius-Wittsten et al. Science Translational Medicine
- Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
- (2021) Myrto K Moutafi et al. Journal for ImmunoTherapy of Cancer
- Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
- (2021) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies
- (2021) Yamin Jie et al. Frontiers in Immunology
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
- (2021) Salma K. Jabbour et al. JAMA Oncology
- First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
- (2021) J. Niu et al. ANNALS OF ONCOLOGY
- CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint
- (2020) Miao Yu et al. Nature Communications
- Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer
- (2020) Yuichi Saito et al. Journal of Thoracic Disease
- Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer
- (2020) Biagio Ricciuti et al. CLINICAL CANCER RESEARCH
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
- (2020) Kenichi Suda et al. Journal of Thoracic Disease
- Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
- (2020) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer research network LUN 14‐179
- (2020) Greg A. Durm et al. CANCER
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer
- (2020) Ziming Hu et al. Molecular Therapy-Oncolytics
- Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
- (2020) Xin Chen et al. Journal for ImmunoTherapy of Cancer
- Role of DNA repair defects in predicting immunotherapy response
- (2020) Jing Zhang et al. Biomarker Research
- LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
- (2020) S. Peters et al. ANNALS OF ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
- (2020) Norah J. Shire et al. PLoS One
- CAR-T cell therapy for lung cancer: a promising but challenging future
- (2020) Shupeng Zhong et al. Journal of Thoracic Disease
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Counteracting CAR T cell dysfunction
- (2020) Mansour Poorebrahim et al. ONCOGENE
- The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
- (2020) Marcin Nicoś et al. Frontiers in Oncology
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
- (2019) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Immunotherapy for small cell lung cancer: mechanisms of resistance
- (2019) Gerhard Hamilton et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- DNA sensing by the cGAS–STING pathway in health and disease
- (2019) Mona Motwani et al. NATURE REVIEWS GENETICS
- Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
- (2019) Kyle B. Lupo et al. Cancers
- Smoking, immunity, and DNA damage
- (2019) Nise H. Yamaguchi Translational Lung Cancer Research
- Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines
- (2019) Andréanne Gagné et al. Journal of Thoracic Oncology
- Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
- (2019) Kaname Nosaki et al. LUNG CANCER
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
- (2019) Melinda L. Telli et al. CLINICAL CANCER RESEARCH
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263
- (2018) Enrico Munari et al. Oncotarget
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
- (2018) Karthik Suresh et al. CHEST
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- NKG2A, a New Kid on the Immune Checkpoint Block
- (2018) John B. Haanen et al. CELL
- Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
- (2018) Jiao Wang et al. Journal for ImmunoTherapy of Cancer
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
- (2017) Andrew W Hahn et al. Immunotherapy
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis
- (2017) Yang Zhang et al. Oncotarget
- A versatile system for rapid multiplex genome-edited CAR T cell generation
- (2017) Jiangtao Ren et al. Oncotarget
- Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
- (2017) Qingyuan Huang et al. OncoImmunology
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- (2016) Eloah Rabello Suarez et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
- (2015) Martin Turcotte et al. CANCER RESEARCH
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
- (2015) I. C. van Gool et al. CLINICAL CANCER RESEARCH
- Role of DNA repair in host immune response and inflammation
- (2015) Fabrícia Lima Fontes et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer
- (2014) Estrella Levy et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Role of non-classical MHC class I molecules in cancer immunosuppression
- (2013) Grazyna Kochan et al. OncoImmunology
- Tim-3, a negative regulator of anti-tumor immunity
- (2012) Ana Carrizosa Anderson CURRENT OPINION IN IMMUNOLOGY
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
- (2012) Hélène Salmon et al. JOURNAL OF CLINICAL INVESTIGATION
- CD73: A Novel Target for Cancer Immunotherapy
- (2010) B. Zhang CANCER RESEARCH
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started